"I am excited to begin this collaboration with NeoStem," said Dr. Bluestone. "Their in-house expertise in development and manufacturing will serve as a complement to my team at UCSF and, through this partnership, I look forward to building on a strong existing foundation, moving these products through clinical development to treat diseases which have long been a focus of my own clinical research."
"NeoStem has core expertise in the development and conduct of cell therapy based trials," said Dr. Andrew L. Pecora, Chief Medical Officer of NeoStem. "This collaboration accelerates the development of our immunomodulatory therapeutic portfolio, enabling the initiation of a Phase 2 trial in type 1diabetes and a Phase 1b/2a trial in steroid resistant asthma. This development significantly diversifies and augments NeoStem's cell therapy pipeline, which includes a Phase 2 cardiovascular clinical trial which is expected to complete enrollment in 2013."
About NeoStem, Inc.
NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.For more information, please visit: www.neostem.com . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's research and development and clinical evaluation efforts for cellular therapies, including with respect to AMR-001 and Tregs, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts